FDA approves novel therapy for blepharoptosis

Upneeq 0.1%, a novel treatment for acquired blepharoptosis, has been approved by the FDA, according to a press release.
Upneeq (oxymetazoline hydrochloride ophthalmic solution, Osmotica Pharmaceuticals) is a once-daily first-in-class alpha-adrenergic agonist, which is thought to target Müller's muscle to elevate the upper eyelid.
In two pivotal phase 3 efficacy studies, Upneeq demonstrated statistically significant improvements over the control in superior visual field and eyelid lift, with a separate safety study showing the drug was well-tolerated when administered every morning in both eyes

Full Story →